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Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus, SARS-CoV. Virus entry into cells is mediated through
interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2). Alanine scanning mutagenesis analysis was performed
to identify determinants on ACE2 critical for SARS-CoV infection. Results indicated that charged amino acids between residues 22 and 57 were
important, K26 and D30, in particular. Peptides representing various regions of ACE2 critical for virus infection were chemically synthesized and
evaluated for antiviral activity. Two peptides (a.a. 22–44 and 22–57) exhibited a modest antiviral activity with IC50 of about 50 μM and 6 μM,
respectively. One peptide comprised of two discontinuous segments of ACE2 (a.a. 22–44 and 351–357) artificially linked together by glycine,
exhibited a potent antiviral activity with IC50 of about 0.1 μM. This novel peptide is a promising candidate as a therapeutic agent against this
deadly emerging pathogen.
© 2006 Elsevier Inc. All rights reserved.Keywords: SARS-CoV; Pseudovirus; ACE2; Peptide; Entry inhibitorIntroduction
Severe acute respiratory syndrome (SARS) is a newly
emerged disease caused by a novel coronavirus designated as
SARS-CoV (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et
al., 2003; Poutanen et al., 2003). During the 2002–2003
epidemic, close to 8100 people were infected worldwide,
among which 774 people died (WHO, 2003). Although the
epidemic was relatively small in scale, the virus had a major
socioeconomic impact and created global health concerns.
Since then, only a few isolated incidences of SARS infection
have been reported, most of which were linked to accidental
exposures to the virus in a laboratory setting. However,
considering the fact that some animal reservoirs that harbor
the virus come into close contact with humans (Guan et al.,⁎ Corresponding author. Department of Medicine, Division of Infectious
Diseases, Case Western Reserve University School of Medicine, 10900 Euclid
Avenue, Cleveland, OH 44106-4984, USA. Fax: +1 216 368 0069.
E-mail address: mcho@case.edu (M.W. Cho).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.01.0292003; Lau et al., 2005; Martina et al., 2003), the virus is highly
likely to resurface again. Development of a vaccine and/or
antiviral agents is critical to prevent future epidemics.
The entry of SARS-CoV into cells is mediated by spike (S)
glycoprotein, which makes it an attractive target for develop-
ment of vaccines and antiviral agents (i.e. entry inhibitors). S
proteins of many coronaviruses are cleaved into, and function
as, two separate subunits, S1 and S2 (Abraham et al., 1990;
Jackwood et al., 2001; Mounir and Talbot, 1993); the S1 subunit
binds a receptor and the S2 subunit induces fusion between viral
and cellular membranes. However, S protein of SARS-CoV
does not appear to be cleaved (Han et al., 2004; Xiao et al.,
2003). Nevertheless, it is presumed to have two functional
domains, and the border between them has been suggested to be
around amino acid 680 (Lio and Goldman, 2004).
The cellular receptor for SARS-CoV has been identified as
angiotensin-converting enzyme-related carboxypeptidase
(ACE2) (Li et al., 2003). ACE2 is a type I integral membrane
protein of 805 amino acids that contains one HEXXH + E zinc-
binding consensus sequence (Donoghue et al., 2000; Tipnis et
16 D.P. Han et al. / Virology 350 (2006) 15–25al., 2000). It is a homolog of angiotensin-converting enzyme
(ACE), which plays an important role in the renin–angiotensin
system for blood pressure homeostasis. ACE does not function
as a receptor for SARS-CoV despite over 40% amino acid
identity and 60% similarity to ACE2 (Li et al., 2003). It has
been reported that DC-SIGNR (a protein related to DC-SIGN
[dendritic cell-specific intercellular adhesion molecule-grab-
bing nonintegrin]) could serve as an alternative receptor (Jeffers
et al., 2004). This finding, however, is contradictory to results
from another study, which suggested that DC-SIGNR, as well as
DC-SIGN, enhance infections mediated by ACE2 but do not
function as receptors by themselves (Marzi et al., 2004). The
precise role of DC-SIGN and DC-SIGNR in SARS-CoV
infection and pathogenesis is yet to be elucidated.
The details of molecular interactions between SARS-CoV S
protein and ACE2 are beginning to be understood. A crystal
structure of ACE2 has been resolved (Towler et al., 2004),
which is facilitating SARS research. A minimal receptor-
binding domain (RBD) has been narrowed down to a 193 amino
acid fragment (residues 318–510), which actually binds ACE2
with greater affinity than does a larger protein fragment
representing the S1 domain (residues 12–672; Wong et al.,
2004). Recent site-directed mutagenesis analyses of ACE2
revealed several amino acid residues important for binding S
glycoprotein (Li et al., 2005b). To characterize interactions
between S protein and the receptor in greater detail, we
performed alanine scanning mutagenesis analyses of ACE2.
The results revealed that charged amino acids between residues
22 and 57 are important for virus infection. We have applied this
information in designing peptide-based entry inhibitors and
identified one that has potent antiviral activity. The results of
our study contribute to better understanding of SARS-CoV
entry and discovery of a novel antiviral agent against the virus.
Results
Determination of amino acid residues on ACE2 critical for
SARS-CoV infection
Three general regions on ACE2 have been identified to be
important for binding S glycoprotein: (1) residues K31 and Y41
on α-helix 1; (2) M82, Y83 and P84 on loop 2; and (3) K353,
D355 and R357 on β-sheet 5 (Li et al., 2005b). These amino
acids are shown in Figs. 1B and C. To evaluate determinants of
interaction between ACE2 and S glycoprotein in greater detail,
we performed alanine scanning mutagenesis analyses. WeFig. 4. Inhibitory effects of ACE2-derived peptides on SARS pseudovirus infection. (A
in an intact protein. Five peptides derived from this fragment are shown (P1–P5). Am
peptide fragments (residues 22–44 and 351–357). The primary sequence of peptide
connected by glycine is shown in the inset. (C) Inhibition of SARS pseudovirus infec
HeLa cells transfected with a plasmid expressing the wild type ACE2 were used. (D
Fig. 1. Structure of ACE2. (A) Sequence alignment of human ACE2 and two homolo
(negative and positive, respectively). K31 and Y41 are highlighted in yellow. (B) A
Locations of amino acids shown to be important for binding S glycoprotein are indic
D615 at the C-terminus is shown as a reference. (C) Close-up view of α-helices 1
residues are shown in green and white, respectively. White dashed line represents anfocused on charged amino acid residues on α-helices 1 and 2 for
two reasons. First, alignment of amino acid sequences of ACE2
and ACE, which does not support SARS-CoV infection,
revealed significant divergence in these helices (only 32% and
24% identity between a.a. 20–79 of ACE2 and two homologous
domains a.a. 41–100 and a.a. 644–703 of ACE, respectively;
Fig. 1A). Second, electrostatic attraction is the predominant
force in protein–protein interactions. Observations that residues
D454 and, to a lesser degree, E452 on S glycoprotein are
important for binding ACE2 (Wong et al., 2004) suggested
possible interactions with oppositely charged amino acids on
ACE2. We were particularly interested in the role of eight
charged residues (other than K31) on α-helix 1 (residues E22,
E23, K26, D30, H34, E35, E37 and D38) because they are
situated near an imaginary line along amino acids already
known to be important for binding S protein (Fig. 1C).
There are a total of 15 charged amino acid residues in α-
helices 1 and 2 (Figs. 1A and C). We successfully mutagenized
all into alanine except for D67. Mutations were introduced into a
plasmid encoding a full-length ACE2 gene (Li et al., 2003).
HeLa cells, which are not susceptible to SARS-CoV infection,
were transfected with plasmids that encode either the wild type
or mutant ACE2 proteins. These cells were infected with non-
replicating SARS pseudoviruses (MuLV pseudotyped with S
glycoprotein; Han et al., 2004) to determine effects of mutations
on viral entry. Disappointingly, mutations had only modest
effects on pseudovirus infectivity (Fig. 2A). Moreover, we were
surprised to observe only about 40% reduction in infectivity for
K31A mutant since Li et al. (2005b) showed near complete loss
of binding activity between ACE2 and S1 protein fragment
containing K31Dmutation. This discrepancy could be due to the
difference between pseudovirus infection and protein–protein
binding assays. Alternatively, the difference could be due to the
use of less drastic mutation in our study (i.e. K to A rather than K
to D). Yet, another possibility was that 1-h virus adsorption
period, which we routinely used, might be too long to observe
subtle differences between the wild type and the mutant proteins.
To explore whether there is a difference between the wild
type and mutant ACE2 in virus entry kinetics, pseudoviruses
were adsorbed to cells for various times between 5 and 120 min.
The kinetic analysis was performed for the wild type and D30A
mutant ACE2 proteins (Fig. 2B). For the wild type ACE2, there
was rapid adsorption of SARS pseudoviruses to cells between
10 and 20 min as indicated by an exponential increase in virus
titer. The virus titer continued to increase up to 90 min, albeit at
a slower rate. 50% maximal infection was achieved by) A crystal structure of an ACE2 peptide fragment (residues 22–57) as it appears
ino acid residues are color-coded as in Fig. 1. (B) A crystal structure of ACE2
P6 is shown. Backbone tracing of a potential conformation of the two fragments
tion as a function of concentration of six different peptides derived from ACE2.
) VSV-G pseudovirus infection was not inhibited even at 100 μM.
gous domains of human ACE. Charged amino acids are indicated in red or blue
crystal structure of ACE2 without the collectrin domain at the C-terminal end.
ated (Li et al., 2005b). α-Helices 1 and 2 are highlighted in yellow. Amino acid
and 2. Charged amino acids are shown in red and blue. Polar and hydrophobic
imaginary line connecting residues known to be important for binding S protein.
Fig. 1.
Fig. 4.
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19D.P. Han et al. / Virology 350 (2006) 15–25approximately 18 min. In contrast, an infection mediated by
D30A mutant ACE2 was significantly slower; it took twice as
long to achieve 50% maximal infection (about 36 min). More
importantly, the difference in pseudovirus infectivity between
the wild type and D30A ACE2 proteins was more pronounced
for 20-min adsorption period compared to 60 min; very little
difference was observed for adsorption periods longer than 60
min. These results suggested that different ACE2 proteins
should be compared at 20 min rather than at 60 min when
infectivity begins to reach a plateau. Therefore, the entire panel
of ACE2 mutants was compared using a 20-min adsorption
period. Under this condition, all of the mutants, except for
K68A, K74A and E75A, exhibited marked reduction in their
ability to support pseudovirus infection (Fig. 2C). The reduction
in infectivity was not due to a defect in protein expression since
all of the mutant ACE2 proteins were expressed at levels similar
to that of WTACE2 (Fig. 2D). Flow cytometry analyses of cells
transfected with either WT or D30A mutant ACE2 proteins
indicated that both proteins are equally expressed on the cell
surface (Fig. 2E). Together, these results indicated the
importance of charged amino acids between residues 22 and 57.
Effects of ACE2 concentration on the rate of pseudovirus
infection
Another parameter that could potentially affect infectivity
of SARS pseudoviruses is the receptor concentration.
Depending on the mutation, the amount of ACE2 protein
required for efficient infection could be different. Similar to
how mutant ACE2 proteins required longer adsorption
period, greater amounts of mutant proteins might be
necessary compared to the wild type. To test this hypothesis,
infectivity of SARS pseudoviruses in HeLa cells transfected
with varying amounts of plasmids encoding either the wild
type or D30A mutant ACE2 proteins was determined. For
this experiment, 1-h adsorption period was used. As
expected, SARS pseudovirus infectivity was dependent on
the amount of plasmids used for both the wild type and
D30A mutant ACE2 (Fig. 3A). However, greater amount of
DNA was needed for D30A mutant than the wild type to
achieve similar infectivity; the half maximal infectivity
points for the wild type and the D30A mutant were
approximately 0.16 μg and 0.41 μg, respectively. To confirm
that expression of ACE2 was proportional to the amount of
plasmid DNA transfected, a Western immunoblot was
performed. As shown in Fig. 3B, ACE2 expression
correlated with the amount of DNA transfected. Expression
levels of the wild type and D30A mutant proteins were
comparable, suggesting that diminished infectivity with
D30A mutant is likely due to reduced affinity to S protein.
An immunoreactive band of an approximately 50 kDa
protein was also detected in this over-exposed blot.Fig. 2. Characterization of mutant ACE2 proteins. (A) Infectivity analyses of the w
pseudovirus entry using the wild type or D30A mutant ACE2. Pseudoviruses were ad
type and mutant ACE2 (20-min adsorption). (D) Western blot analyses of ACE2 pro
D30A mutant ACE2 by flow cytometry. Cells transfected with pcDNAwere used aAlthough the exact nature of the protein is unknown, it
most likely is a cleavage product of ACE2 since the band
intensity correlated with that of the authentic ACE2.
Since the difference in infectivity between the wild type
and D30A mutant ACE2 was the greatest when 0.25 μg of
plasmid DNA was used, the entire panel of ACE2 mutants
was evaluated using 0.25 μg. Pseudovirus infectivity was
assessed using two different adsorption periods (40 and 60
min). When 60-min adsorption period was used, significant
reduction in infectivity was observed only for K26A and
D30A mutants (Fig. 3C). Using 40-min adsorption, infectivity
was markedly reduced not only for K26A and D30A mutants,
but also for E56A and E57A (Fig. 3D). Together, these results
suggested that K26 and D30 might be most critical for
interaction with S glycoprotein. The overall infectivity pattern
was very similar to 20-min adsorption period using 1 μg of
plasmid DNA (Fig. 3D compared to Fig. 2C). Consistent with
results from adsorption kinetics analyses (Fig. 2), ACE2
mutants K68A, K74A and E75A exhibited no defect in
supporting SARS pseudovirus infections.
Inhibition of SARS-CoV infection using an ACE2-derived
peptide
Knowing that charged amino acids between residues 22
and 57 of ACE2 were important for SARS-CoV entry, we
next examined whether we could design peptide-based virus
entry inhibitors. We rationalized that ACE2-derived peptides
that bind S glycoprotein with high affinity should be able to
block ACE2-S protein interaction and inhibit virus infection.
Five peptides were chemically synthesized: a.a. 22–31, 30–
38, 33–41, 22–44 and 22–57 (peptides P1 through P5,
respectively; Fig. 4A). To assess antiviral activity, pseudo-
viruses were preincubated with varying concentrations of each
peptide for 20 min and then allowed to infect HeLa cells
expressing ACE2. As shown in Fig. 4C, shorter peptides (P1,
P2 and P3) exhibited only weak antiviral activity. Longer
peptides P4 and P5 were more active with approximately 50%
inhibitory concentrations (IC50) of 50 μM and 6 μM,
respectively.
To improve antiviral activity, we considered other possibil-
ities of incorporating residues 82–84 or 353–357 since they
were also shown to be important for binding S protein (Li et al.,
2005b). Upon close examination of the ACE2 crystal structure,
we noticed that the spacing between S44 and L351 was
sufficiently narrow enough to be filled by a single amino acid
(Fig. 4B). However, the directionality of the E22–S44 fragment
was opposite from that of the L351–K353 fragment. Glycine,
which has the smallest side chain, has high propensity to form
reverse turns. Thus, an artificial peptide of 31 amino acids was
synthesized by joining fragments 22–44 and 351–357 with
glycine (peptide P6; Fig. 4B). To our surprise, peptide P6ild type and mutant ACE2 (60-min adsorption). (B) Kinetic analyses of SARS
sorbed to cells for various times as indicated. (C) Infectivity analyses of the wild
tein expression. (E) Comparison of cell surface expression of the wild type and
s a negative control.
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approximately 0.1 μM, which is 60- and 500-fold lower than
peptides P5 and P4, respectively (Fig. 5C). This was somewhat
unexpected since P6 is different from P4 only by eight amino
acids. Slightly higher IC50 value (0.3 μM) was observed when
pseudovirus infections were carried out using VeroE6 cells (data
not shown). The inhibitory effect is specific against SARS-CoV
since none of the peptides inhibited VSV-G-pseudotyped MuLV
even at 100 μM (Fig. 4D). The specificity is further evidenced
by the fact that none of the peptides was effective against
viruses pseudotyped with MuLV envelope protein (data not
shown). No cytotoxicity was observed for peptides P4, P5 or P6
even at 200 μM based on neutral red uptake assay (data not
shown).
Discussion
In this study, we examined the importance of charged amino
acids in the first two α-helices of ACE2 in mediating SARS-
CoV infection. Out of the total 14 residues evaluated, eleven
amino acids between the residues 22 and 57 were important
(E22, E23, K26, D30, K31, H34, E35, E37, D38, E56 and E57).
The two most critical residues were K26 and D30. This result
and the fact that all 9 charged residues between E22 and D38
played an important role were not unexpected given that they
are situated in close proximity to the imaginary line that
connects amino acids previously shown to be important for
binding S protein fragments (Li et al., 2005b; Fig. 1C). In this
regard, we were a bit surprised to see the importance of residues
E56 and E57, but not K68, K74 or E75. None of the amino acids
we identified was critical enough to inhibit virus infection
completely. Mutants were merely less efficient than the wild
type ACE2; they required either longer adsorption period or
greater amounts to achieve the wild type level of infectivity.
This is to be expected since there are multiple determinants of
interaction between S protein and ACE2.
During the preparation of our manuscript, a crystal structure
of ACE2 bound to an S protein fragment containing the RBD
(residues 306 to 527) was published (Li et al., 2005a; Fig. 5A).
ACE2 residues that made direct contact with the RBD included
Q24, T27, K31, H34, E37, D38, Y41, Q42, L45, L79, M82,
Y83, N90, Q325, E329, N330, K353 and G354. Although the
crystal structure confirmed our results regarding the importance
of K31, H34, E37 and D38, the study's findings did not include
many of the residues we found to be important, including E22,
E23, K26, D30, E35, E56 and E57 (Figs. 5B and C). We are
particularly puzzled at the fact that neither K26 nor D30, the two
residues that appeared to be most critical in our study, made
contacts with the RBD.
There are a few possible reasons that could account for the
apparent discrepancy. The simplest explanation is that resultsFig. 3. Characterization of mutant ACE2 proteins. (A) Analyses of SARS pseudovir
indicated amounts of plasmids encoding either wild type or D30Amutant ACE2. The
DNA. (B) Western blot analyses of ACE2 expression in cells transfected with indicate
Infectivity analyses of the wild type and mutant ACE2 (0.25 μg plasmid, 60-min ad
plasmid, 40-min adsorption).from the two studies were obtained using different S proteins.
The structural study was based on a small fragment of S protein
containing just the RBD. In contrast, our study was based on an
intact protein. It is possible that residues other than the ones in
the RBD could be making contacts with amino acids we
identified.
Another possible explanation is that the conformation of the
receptor-binding motif (RBM, residues 424 to 494) in the crystal
structure could be somewhat different from the one in an intact S
glycoprotein. It was previously shown that a D454Amutation on
S protein completely abolished association of ACE2 with either
the RBD (residues 318–510) or the S1 protein fragment
(residues 12–672; Wong et al., 2004). Based on this result, we
suspected that D454 residue might be directly interacting with
ACE2. However, D454 was quite distant from ACE2 in the
crystal structure (Fig. 5C). This seemingly contradictory result
raises a possibility that the RBD used to solve the crystal
structure may have different conformation than the one used to
analyze D454A mutation; they are different in length and were
prepared from different cellular sources (Sf9 insect cells vs.
293T human cells, respectively). Although it is possible that
D454 plays an indirect role in binding ACE2 (e.g. in maintaining
a proper conformation of the RBM), it is a little difficult to
appreciate such a drastic effect from an amino acid far away from
the receptor-contacting site, especially when the residue is
located in a loop. A crystal structure of a larger S1 fragment is
needed to resolve this issue.
A third possible reason for the discrepancy could be the
difference in the nature of the two studies. The footprint analysis
based on a crystal structure identifies only the residues that are
making initial contacts with the RBD. In contrast, our study
examined the entire virus entry process and identifies residues
that are functionally important, either directly or indirectly.
Therefore, the residues we identified could be involved not just
in the initial binding of S glycoprotein, but in subsequent steps in
the membrane fusion process. Events that follow binding of S
glycoprotein to ACE2 are unknown. Additional studies are
necessary to better understand the molecular details of SARS-
CoV entry.
In this study, we examined anti-SARS activity of six
chemically synthesized peptides derived from ACE2. The
peptide with the most potent antiviral activity was P6, which
is comprised of two discontinuous fragments 22–44 and 351–
357 connected by glycine. Peptide P6 is just eight amino
acids longer than P4. Yet, it was about 500-fold more
effective. In contrast, P5, which is 13 amino acids longer than
P4, was only about 8-fold more effective. It is not clear as to
exactly why P6 is so much more potent than P4 or P5
peptides. The simplest explanation is that there are more
residues on P6 that interact with S glycoprotein than either P4
or P5 peptides. Site-directed mutagenesis analyses indicatedus infectivity as a function of ACE2 amount. HeLa cells were transfected with
total amount of DNA transfected remained constant (1 μg) using pcDNA as filler
d amounts of plasmids expressing either wild type or D30A mutant proteins. (C)
sorption). (D) Infectivity analyses of the wild type and mutant ACE2 (0.25 μg
Fig. 5. Structural analyses of interactions between ACE2 and RBD. (A) A bird's eye view of a crystal structure of the RBD of S protein (lime) bound to ACE2 (gray)
(Li et al., 2005a). The RBM portion of the RBD is colored pink. The surface of amino acids that actually make contacts with ACE2 is shown in purple. The first two α-
helices of ACE2 are shown in yellow as a reference. ACE2 residues that make contacts with RBM are shown in green. Charged residues shown to be important for
pseudovirus infection in this study are shown in either red or blue. (B) A top view of the co-crystal structure. Residues shown to be important for infection but have not
shown to make contacts with the RBD are indicated. (C) A side view of the co-crystal structure. The position of D454 residue of S protein is shown in orange. (D) A
potential binding site of the P6 peptide on the RBD. Peptide fragments 22–44 and 351–357 are shown in yellow and cyan, respectively. The RBM is shown in pink,
while the rest of the RBD is shown in lime.
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binding a S1 protein fragment (Li et al., 2005b). Furthermore,
residues K353 and G354 make direct contacts with the RBM
of S protein as shown in the crystal structure (Li et al.,
2005a). Thus, four of seven residues between 351 and 357
play a role in virus infection. In contrast, only 3 of 13 amino
acids between residues 45 and 57 are known to be involved
in binding or mediating SARS infection (L45, E56 and E57;
Li et al., 2005a and this study). However, the qualitative
aspect of the interaction could be more important than simply
the number of amino acids that interact between ACE2 and S
protein. An interesting question that remains to be answered
is whether a peptide fragment containing just the residues
351–357 could inhibit SARS infection. Assessing antiviral
activity of this peptide could provide insights as to whether
there is synergy between residues 22–44 and 351–357 in the
context of the P6 peptide.At the present time, we understand neither the P6 peptide
structure nor how it interacts with S glycoprotein. If the peptide
folds into a structure as it appears in the crystal structure of
ACE2, then the peptide should bind the RBM as illustrated in
Fig. 5D; the contact sites on S protein would include residues
Y436, Y440, Y442, N473, Y475, N479, Y484, T486, T487,
G488 and Y491. It is possible, however, that P6 may fold
slightly differently as a free peptide. For one thing, residues 22–
44 form a highly amphipathic α-helix; while one side of the
helix that binds S protein is highly polar with many charged
amino acids, the opposite side that faces interior of ACE2 is
hydrophobic (Fig. 4B). These hydrophobic amino acids would
be exposed to an aqueous environment in a free peptide, which
might make the α-helical structure less stable. Secondly,
although residues 351–357 are a part of β-turn-β structure in
an intact ACE2, they might not exist in the same conformation
due to the absence of other residues that support formation of
23D.P. Han et al. / Virology 350 (2006) 15–25this secondary structure. Regardless, potent antiviral activity of
the P6 peptide suggests that its conformation most likely
resembles the one in the ACE2 crystal structure, at least when it
is bound to S protein.
It has been shown that the interaction between S glycopro-
tein and ACE2 plays a critical role in SARS pathogenesis (Kuba
et al., 2005); binding of S protein to ACE2 leads to
downregulation of the receptor, which results in deregulation
of the renin–angiotensin system and eventual lung injury.
Therefore, our P6 peptide is a strong therapeutic candidate that
would not only inhibit SARS-CoV infection but also prevent
severe and often lethal lung failure.
Materials and methods
Plasmids and site-directed mutagenesis
A plasmid encoding full-length wild type human ACE2
(hACE2) was generously provided by Dr. Michael Farzan (Li et
al., 2003). Site-directed mutagenesis of hACE2 was performed
using QuickChangeXL Site-Directed Mutagenesis System
(Stratagene) with PfuTurbo DNA polymerase. Fourteen pairs
of primers were used to generate mutants. Primers were 33
nucleotides long, and the nucleotide changes for each of the
amino acids mutated are indicated as follows: E22: gag to gCg;
E23: gaa to gCa; K26: aag to GCg; D30: gac to gCc; K31: aag to
GCg; H34: cac to GCc; E35: gaa to gCa; E37: gaa to gCa; D38:
gac to gCc; E56: gaa to gCa; E57: gag to gCg; K68: aaa to GCa;
K74: aag to GCg; and E75: gaa to gCa. Mutations were verified
by sequencing.
Cell culture and pseudovirus production
Cell lines TELCeB6 (Schnierle et al., 1997), HeLa and
VeroE6 were maintained in Dulbeco's modified Eagle medium
(DMEM) supplemented with 5–7% fetal bovine serum, 2 mM
L-glutamine and penicillin–streptomycin antibiotics. Cells were
cultured in 5% CO2 incubators at 37 °C. Pseudoviruses, which
encode β-galactosidase, were produced as we have previously
described (Han et al., 2004). Briefly, TELCeB6 cells, which
continuously release murine leukemia virus (MuLV) particles,
were transfected with plasmids encoding S glycoprotein
(pHCMV-S; Han et al., 2004) or G glycoprotein of vesicular
stomatitis virus (pHCMV-G; Burns et al., 1993) using
Lipofectin (Invitrogen) as per manufacturer's protocol. Three
days post-transfection, cell culture medium was harvested and
subjected to centrifugation (1700×g, 10 min) to remove cell
debris. Supernatant was aliquoted, stored at −80 °C and used as
a virus stock.
To produce pseudoviruses without repeated transfections,
we generated TELCeB6 cells that stably express S glycopro-
tein. TELCeB6 cells were co-transfected with pHCMV-S and
pcDNA3.1 (Invitrogen), which encodes a neomycin resistance
gene. Transfected cells were selected in the growth medium
containing Geneticin (Invitrogen; 0.4 μg/ml). Geneticin-
resistant clones were isolated, expanded and those able to
produce high titers of SARS pseudoviruses were selected.Although cells were subsequently maintained in the absence of
Geneticin, they continuously produced pseudoviruses with
titers of 5–6 × 103 per ml. Virus titer was determined in VeroE6
cells.
Pseudovirus infections
Pseudovirus infections were done in VeroE6 cells (96-well
plates) or in HeLa cells (24-well plates) transfected with
plasmids encoding either the wild type or mutant ACE2
proteins. Cells were transfected with 1 μg (or indicated
amounts) of plasmid DNA per well using Lipofectin. After
overnight incubation, culture medium was replaced. Approx-
imately 24 h post-transfection, cells were infected with about
150 infectious units of pseudoviruses. Pseudoviruses were
allowed to adsorb onto cells for various times as indicated.
Cells were subsequently washed with PBS to remove
unadsorbed viruses, and fresh medium was added. Infections
were allowed to proceed for additional 1.5 days at which time
infected cells were stained with X-Gal as previously
described (Han et al., 2004). Although blue cells can be
detected within a few hours, staining was routinely done
overnight because it yields a stronger signal. Pseudovirus-
infected cells were quantified visually using inverted
microscope.
Peptide synthesis and inhibition assays
Peptides were synthesized by Fmoc strategy on an Omega
396 synthesizer (Advanced ChemTech, Louisville, KY) using
solid phase chemistry. Synthesis was performed by coupling
amino acid esters of 1-hydroxybenzotriazole using 1,3 diiso-
propylcarbodiimide. Amino- and carboxyl-termini were acety-
lated and amidated, respectively. Deprotection of Na-Fmoc
group was accomplished by 25% piperidine in dimethylforma-
mide. After the synthesis, peptides were cleaved from the solid
support and deprotected using a modified reagent K cocktail
consisting of 88% TFA, 3% thioanisole, 5% ethanedithiole, 2%
water and 2% phenol. The cocktail-containing peptides were
filtered on a Quick-Snap column, and the filtrate was collected
in 20 ml ice-cold butane ether. Peptides were precipitated (1 h at
−20 °C), centrifuged and washed twice with ice-cold methyl-t-
butyl ether. Peptides were dissolved in 25% acetonitrile and
lyophilized to complete dry powder. The expected molecular
weights of peptides were verified by matrix-assisted laser
desorption ionization time-of-flight (MALDI-TOF) mass spec-
trometry. Peptides were dissolved in PBS (0.5 to 2 mM
depending on peptides) and stored at −80 °C until use.
To evaluate antiviral activity, pseudoviruses (SARS-S or
VSV-G) were preincubated with indicated concentrations of
peptides for 20 min at 37 °C. Subsequently, the virus–peptide
mixture was added to VeroE6 cells or HeLa cells transfected
with a plasmid encoding the wild type ACE2. After a 20-min
adsorption period, the virus inoculum was removed and fresh
culture medium was added. Following additional 1.5 days of
infection, infected cells were stained and virus-infected cells
were quantified as described above.
24 D.P. Han et al. / Virology 350 (2006) 15–25Western blot and flow cytometry analyses
HeLa cells grown in 24-well plates were transfected with
indicated amounts of plasmid DNA encoding either the wild
type or mutant ACE2 using Lipofectin. After overnight
incubation, culture medium was replaced. At 48 h post-
transfection, culture medium was removed and cells were
lysed with a hypotonic buffer containing non-ionic detergent
(10 mM Tris, pH 7.5, 10 mMNaCl, 1.5 mMMgCl2 and 1% NP-
40). Nuclei and insoluble cell debris were removed by
centrifugation. Cell lysates were subjected to SDS-PAGE
followed by electrotransfer to nitrocellulose membranes for
Western blots. ACE2 proteins were detected with rabbit anti-
ACE2 polyclonal antibodies (ΨProSci Inc.) followed by goat
anti-rabbit IgG conjugated with horseradish peroxidase
(Pierce). Protein bands were visualized with SuperSignal
chemiluminescent substrates (Pierce) according to a manufac-
turer's protocol.
For flow cytometry, transfected cells were harvested by
scraping them into culture medium and centrifugation. Cells
were washed twice with PBS and resuspended in 50 μl of
Stain Buffer (BD Pharmingen) containing 0.1 μg/ml of Mouse
IgG2A anti-human ACE2 ectodomain monoclonal antibody
(R&D Systems, # MAB9331). After staining for 1 h at 4 °C,
cells were washed three times with PBS and resuspended in 50
μl of Stain Buffer containing goat-anti mouse IgG conjugated
to FITC (BD Pharmingen). After staining for 1 h at 4 °C, cells
were washed three times with PBS, resuspended in 300 μl of
PBS and subjected to flow cytometry analysis using BD
FACSCalibur.
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